[Studies on transdermal delivery system of isosorbide dinitrate]

Area of Science:

• Pharmacology
• Materials Science

Context:

• Transdermal drug delivery systems (TDDS) offer advantages over oral administration for managing cardiovascular conditions.
• Isosorbide dinitrate (ISDN) is a vasodilator commonly used to treat angina.
• Optimizing ISDN release kinetics and stability is crucial for effective and consistent therapeutic outcomes.

Purpose:

• To develop and characterize a novel transdermal delivery system (ISDN-TDS) for isosorbide dinitrate.
• To investigate the factors influencing ISDN release from the developed TDS.
• To evaluate the release kinetics and compare the stability of ISDN-TDS with a commercial product (Frandol tape-s).

Summary:

• A new transdermal delivery system for isosorbide dinitrate (ISDN-TDS) was successfully developed, incorporating backing, drug reservoir, control membrane, contact adhesive, and protective layers.
• The study systematically analyzed the impact of the drug reservoir, solvent, control membrane, viscosity, and the penetration enhancer azone on ISDN release.
• ISDN demonstrated zero-order release kinetics through excised skin over 48 hours, with sustained release from ISDN-TDS lasting at least 72 hours and a mean permeation rate of 13.76 µg/h/cm².
• The ISDN-TDS exhibited superior stability and a more consistent release profile compared to Frandol tape-s, which followed a linear Q vs t¹/² relationship with a release flux of 114.39 µg/h/cm².

Impact:

• The developed ISDN-TDS provides a potentially more effective and stable alternative for isosorbide dinitrate administration.
• This research contributes to the advancement of transdermal drug delivery technologies for cardiovascular therapeutics.
• The findings may lead to improved patient compliance and therapeutic efficacy in managing conditions requiring isosorbide dinitrate treatment.